Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3

Rhea-AI Filing Summary

Aura Biosciences, Inc. reported that Chief Operating Officer Susan Abu-Absi filed an initial statement of beneficial ownership as a Form 3 reporting person. The filing lists her status as an officer but includes no reported transactions or derivative positions in this submission.

Key Figures

Reported buy transactions: 0 Reported sell transactions: 0 Derivative transaction count: 0

3 metrics

Reported buy transactions 0 Buy transaction count in Form 3 transaction summary

Reported sell transactions 0 Sell transaction count in Form 3 transaction summary

Derivative transaction count 0 DerivativeTransactionCount in Form 3 transaction summary

FAQ

What does Aura Biosciences (AURA) disclose about Susan Abu-Absi in this Form 3?

The Form 3 identifies Susan Abu-Absi as a reporting person of Aura Biosciences (AURA) and notes that she is the company’s Chief Operating Officer, establishing her insider status for future ownership and transaction reporting.

Are any stock transactions reported for Susan Abu-Absi in Aura Biosciences (AURA)’s Form 3?

No transactions are reported for Susan Abu-Absi in this Form 3. The structured data show a zero count for buys, sells, derivative transactions, and exercises, indicating only an initial insider-status filing at this time.

Does Aura Biosciences (AURA) report any derivative positions for Susan Abu-Absi in this Form 3?

The Form 3 data show no derivative positions reported for Susan Abu-Absi. The derivativeSummary is empty and the derivativeTransactionCount is zero, meaning no options or similar instruments are detailed in this filing.

Is Susan Abu-Absi a 10% owner of Aura Biosciences (AURA) according to this Form 3?

The Form 3 indicates that Susan Abu-Absi is not listed as a 10% owner. She is identified specifically as an officer, holding the title of Chief Operating Officer, with the ten-percent-owner flag set to zero.

Does the Aura Biosciences (AURA) Form 3 mention any Rule 10b5-1 trading plan for Susan Abu-Absi?

The data include a document-level 10b5-1 plan indicator, which is null for this filing. This reflects that there is no affirmative statement here about trades made under a Rule 10b5-1 plan for Susan Abu-Absi.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/12/2026 - 04:05 PM Accepted by SEC EDGAR 08/12/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Abu-Absi Susan

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/10/2026

3. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Amy Elazzouzi, as Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)